AbbVie Inc. Stock Underperforms Wednesday When Compared To Competitors

Goldman Sachs Group Inc

Change company Symbol lookup

Select an option...

GS Goldman Sachs Group Inc

ONON On Holding AG

XNCR Xencor Inc

ALT Altimmune Inc

RZLT Rezolute Inc

BNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNs

SGFY Signify Health Inc

FRC First Republic Bank

BACK IMAC Holdings Inc

LYLT Loyalty Ventures Inc

Financials : Capital Markets | Large Cap Value

Company profile

The Goldman Sachs Group, Inc. is a global financial institution that delivers a range of financial services across investment banking, securities, investment management and consumer banking to a diversified client base that includes corporations, financial institutions, governments and individuals. The Company segments include Global Banking & Markets, Asset & Wealth Management and Platform Solutions. The Global Banking & Markets segment includes financing, advisory services, risk distribution, and hedging for its institutional and corporate clients, including Fixed Income, Currency and Commodities (FICC) and Equities, Investment Banking and Marquee. The Asset & Wealth Management segment includes advice, investing, and execution for institutions and individuals across public and private markets. The Platform Solutions segment includes consumer platforms, such as partnerships offering credit cards and point-of-sale financing, and transaction banking and other platform businesses.

AbbVie Inc. Stock Underperforms Wednesday When Compared To Competitors

4:33 pm ET January 18, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) slid 2.38% to $149.20 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.56% to 3,928.86 and Dow Jones Industrial Average falling 1.81% to 33,296.96. This was the stock's second consecutive day of losses. AbbVie Inc. closed $26.71 short of its 52-week high ($175.91), which the company achieved on April 8th.

The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 1.51% to $169.76 and Pfizer Inc. (PFE) fell 2.34% to $45.00. Trading volume (6.2 M) eclipsed its 50-day average volume of 5.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 18, 2023.

(END) Dow Jones Newswires

January 18, 2023 16:33 ET (21:33 GMT)